WallStSmart

Johnson & Johnson (JNJ)vsMaravai Lifesciences Holdings Inc (MRVI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 47733% more annual revenue ($97.93B vs $204.73M). JNJ leads profitability with a 21.5% profit margin vs -51.1%. JNJ earns a higher WallStSmart Score of 57/100 (C).

JNJ

Buy

57

out of 100

Grade: C

Growth: 4.7Profit: 8.5Value: 4.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.64

MRVI

Avoid

31

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 2/9Altman Z: 0.32

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JNJ5 strengths · Avg: 8.8/10
Market CapQuality
$615.36B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
24.8%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
21.5%9/10

Keeps 22 of every $100 in revenue as profit

Operating MarginProfitability
28.6%8/10

Strong operational efficiency at 28.6%

Free Cash FlowQuality
$3.39B8/10

Generating 3.4B in free cash flow

MRVI1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
40.5%10/10

Revenue surging 40.5% year-over-year

Areas to Watch

JNJ3 concerns · Avg: 2.7/10
P/E RatioValuation
29.1x4/10

Moderate valuation

PEG RatioValuation
4.142/10

Expensive relative to growth rate

EPS GrowthGrowth
-1.0%2/10

Earnings declined 1.0%

MRVI4 concerns · Avg: 2.8/10
Operating MarginProfitability
1.1%3/10

Operating margin of 1.1%

Debt/EquityHealth
1.283/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-49.4%2/10

ROE of -49.4% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.

Bull Case : MRVI

The strongest argument for MRVI centers on Revenue Growth. Revenue growth of 40.5% demonstrates continued momentum.

Bear Case : JNJ

The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.

Bear Case : MRVI

The primary concerns for MRVI are Operating Margin, Debt/Equity, Piotroski F-Score.

Key Dynamics to Monitor

JNJ profiles as a mature stock while MRVI is a hypergrowth play — different risk/reward profiles.

MRVI carries more volatility with a beta of 0.65 — expect wider price swings.

MRVI is growing revenue faster at 40.5% — sustainability is the question.

JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (57/100 vs 31/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Maravai Lifesciences Holdings Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human disease research in the United States and internationally. The company is headquartered in San Diego, California.

Visit Website →

Want to dig deeper into these stocks?